CNS Pharmaceuticals Inc Cash Flow Conversion Efficiency
CNS Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has a cash flow conversion efficiency ratio of -0.194x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.54 Million) by net assets ($18.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CNSP market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of CNS Pharmaceuticals Inc (2017–2025)
Cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how CNS Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CNS Pharmaceuticals Inc stock quote for real-time trading data and today's change.
CNS Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
CNS Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CNS Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review CNS Pharmaceuticals Inc (CNSP) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huadi International Group Co Ltd
NASDAQ:HUDI
|
-0.053x |
|
Ignite Ltd
AU:IGN
|
0.302x |
|
SolTech Energy Sweden AB
ST:SOLT
|
-0.008x |
|
Zwahlen et Mayr SA
SW:ZWM
|
-0.106x |
|
IMPIANTI S.P.A.
F:F67
|
N/A |
|
Ictsi Jasa Prima Tbk
JK:KARW
|
-0.039x |
|
Tri-Mode System M Bhd
KLSE:0199
|
0.023x |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
-11.870x |
Annual Cash Flow Conversion Efficiency for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2025. Also see CNSP asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.52 Million | $-13.81 Million | -3.054x | -10.22% |
| 2024-12-31 | $6.18 Million | $-17.11 Million | -2.771x | -186.84% |
| 2023-12-31 | $-4.43 Million | $-14.14 Million | 3.190x | +345.76% |
| 2022-12-31 | $8.13 Million | $-10.56 Million | -1.298x | +36.50% |
| 2021-12-31 | $6.62 Million | $-13.54 Million | -2.045x | -289.68% |
| 2020-12-31 | $13.95 Million | $-7.32 Million | -0.525x | -12.23% |
| 2019-12-31 | $7.60 Million | $-3.55 Million | -0.467x | -135.85% |
| 2018-12-31 | $-549.30K | $-716.38K | 1.304x | -31.96% |
| 2017-12-31 | $-58.53K | $-112.20K | 1.917x | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more